论文部分内容阅读
急性早幼粒细胞白血病(APL)为AML的一种特殊亚型,具有特殊的形态特征和染色体易位t(15;17)及PML-RAR α融合基因,根据PML基因断裂点不同分为长型(L),短型(S)。变异型(V)。全反式维甲酸(ATRA)对具有t(15;17)的APL患者的诱导缓解(CR)率高达95％,CR后强烈化疗可使60％的患者长期无病生存,然而仍有40％患者复发,另外ATRA治疗中具有危及生命的维甲酸(RA)综合征。本文旨在阐述APL患者临床及生物学特征(台湾),CD2表达与PML-RAR α
Acute promyelocytic leukemia (APL) is a special subtype of AML, with special morphological features and chromosomal translocation t (15; 17) and PML-RAR α fusion gene, divided into long according to the breakpoint of PML gene Type (L), Short (S). Variant (V). All-trans retinoic acid (ATRA) has an induced remission (CR) rate of 95% in patients with APL with t(15;17). Post-CR strong chemotherapy can lead to long-term disease-free survival in 60% of patients, yet 40% The patient relapsed and had a life-threatening retinoic acid (RA) syndrome in ATRA treatment. This article aims to describe the clinical and biological characteristics of APL patients (Taiwan), CD2 expression and PML-RAR α